Toggle navigation 
About Us 
Background
Leadership
Scientific Advisors & Academic Collaborators
Partnering
Contact Us
Overview 
Human Microbiome
Clinical Microbiota Development
Recurrent 
Clostridium Difficile
 Infection
Platform & Pipeline 
Full-Spectrum Microbiota™
CP101 (PRISM 3)
Other Indications
Careers
News
Crestovo has merged with Finch Therapeutics to form Finch Therapeutics Group
Click here
 to be directed to the Finch Therapeutics Group website. 
PRISM 3
, a clinical trial in recurrent CDI is actively enrolling patients. For more information, please visit 
clinicaltrials.gov
.
LEARN MORE
OVERVIEW
PIPELINE
CAREERS
NEWS
10.23.2017
Finch Therapeutics and Crestovo Announce Merger to Form Finch Therapeutics Group, a Leading, Fully Integrated Microbiome Company
Merged entity includes a diverse pipeline of Full-Spectrum MicrobiotaTM and Rationally-Selected MicrobiotaTM products, an innovative discovery platform, large-scale manufacturing capabilities
FULL ARTICLE
6.27.2017
Crestovo Doses Patients in PRISM 3, a Clinical Trial of CP101, a Microbiome Therapy for the Prevention of Recurrent 
Clostridium difficile
 Infection
FULL ARTICLE
FULL-SPECTRUM MICROBIOTA
TM
At Crestovo, we are leveraging our industry-leading Full-Spectrum Microbiota™ (FSM™) platform to develop 
therapeutics
 that harness the human gut microbiome to restore diversity of healthy microorganisms. Through this approach, we are working to treat conditions with significant unmet medical need where patients are suffering from dysbiosis, including recurrent 
Clostridium difficile
 infection (CDI).
VISIT OUR PLATFORM
JOIN OUR TEAM
Crestovo is looking for dynamic, driven individuals to join our team that is focused on treating serious diseases, pioneering breakthroughs in the biopharmaceutical industry and making a positive impact on patients’ lives. Ready to be part of a world-class team at the forefront of the microbiome movement?
CAREER OPPORTUNITIES

					© 2018 CRESTOVO
					
·
Terms of Use
·
Contact
Top